MBX Biosciences Future Growth
Future criteria checks 0/6
MBX Biosciences's earnings are forecast to decline at 26.3% per annum. EPS is expected to grow by 8.8% per annum.
Key information
-26.3%
Earnings growth rate
8.8%
EPS growth rate
| Pharmaceuticals earnings growth | 23.5% |
| Revenue growth rate | n/a |
| Future return on equity | -29.5% |
| Analyst coverage | Low |
| Last updated | 08 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -105 | N/A | -110 | 3 |
| 12/31/2025 | N/A | -80 | -80 | -74 | 4 |
| 12/31/2024 | N/A | -65 | -62 | -58 | 4 |
| 6/30/2024 | N/A | -47 | -44 | -43 | N/A |
| 3/31/2024 | N/A | -39 | -37 | -37 | N/A |
| 12/31/2023 | N/A | -33 | -32 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MBX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MBX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if MBX's revenue is forecast to grow faster than the US market.
High Growth Revenue: MBX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MBX is forecast to be unprofitable in 3 years.